Work

Abstract LB-B30: First in human, dose escalation trial of the combination of dabrafenib, trametinib, and navitoclax in patients with BRAF mutant solid tumors

Year: 2018

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-17-lb-b30

Authors: Ryan J. Sullivan, Janice Mehnert, Hussain Tawbi, Donald Lawrence, Keith Flaherty, Helen Chen, Naoko Takabe, Michael Davies

Institutions: Harvard University, Massachusetts General Hospital, Rutgers, The State University of New Jersey, The University of Texas MD Anderson Cancer Center, National Cancer Institute

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2787318311

Cites:

Cited by: 5

Related to: 10